Table 2.

Overall characteristics of the studies.

First Author	Buchroithner	Cho	Kong	Sampson	Ursu	Wakabayashi	Weller	Wen	Wheeler	Total	Median
Year	2018	2011	2017	2010	2017	2018	2017	2019	2016
Trial Phase	II	II	III	II	II	II	III	II	II
Country of Publication	Austria	China	Korea	USA	France	Japan	Switzerland/USA	USA	USA
Age (low limit)	19	14	19	29	42	22	51	22	32		27
Age (high limit)	70	70	69	71	78	75	64	81	72		72.2
Patients Included (n)	76	34	180	35	81	122	405	124	182	1239
Immunoteraphy group (n)	34	18	91	18	39	59	195	81	48	583
Immunotherapy group (%)	44.73684211	52.94117647	50.55555556	51.42857143	48.14814815	48.36065574	48.14814815	65.32258065	26.37362637		47
Control group (n)	42	16	89	17	42	63	210	43	134	656
Control group (%)	55.26315789	47.05882353	49.44444444	48.57142857	51.85185185	51.63934426	51.85185185	34.67741935	73.62637363		52.9
Immunotherapy type used	Tumor lysate-charfed autologous dendritic cells (Audencel)	Whole-cell lysate dendritic cell vaccine	Autologous cytokine- induced killer cells	PEPvIII vaccine (13-amino acid peptide w/ an additional terminal cystine that spans the EGFRvIII mutation)	Immunostimulating oligodeoxynucleotides containing unmethylated cytoside-guanosine motifs (CpG-ODN)	Interferon β	Rindopepimut	ICT-107 (autologous dendritic cells)	Aglatimagene besadenovec (AdV- tk) plus valcyclovir (gene-mediated cyottoxic immunotherapy)
Male (n)	51	16	102	NA	48	73	254	75	NA	619
Male %	67.10526	47.05882	56.66667	NA	59.25926	59.83607	62.71605	60.48387	NA		60.5
Female (n)	25	18	78	NA	33	49	151	49	NA	403
Female %	32.89474	52.94118	43.33333	NA	40.74074	40.16393	37.28395	39.51613	NA		39.4